Diagnosis and management of uveal melanoma

Melanoma Insights for Professionals

Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic approaches to metastatic disease are vital.

In this podcast, A/Prof Matteo Carlino interviews fellow Medical Oncologist Prof Georgina Long AO and Ophthalmologist A/Prof Max Conway on our latest understanding of the diagnosis and management of early and advanced uveal melanoma, including:

• presentation and diagnostic process
• current treatment options and rationale for local therapy in early melanoma
• determining which patients are suitable for screening for metastatic disease
• developing a surveillance plan based on risk of recurrence
• the different activity of systemic therapy in uveal versus cutaneous melanoma
• importance of the multidisciplinary team
• activity of tebentafusp in advanced uveal melanoma
• the current clinical trial landscape.

This podcast is suitable for Oncologists, Ophthalmologists, GPs, Oncology Nurses and other healthcare professionals.

SPEAKERS

• A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals Clinical Associate Professor, The University of Sydney
• Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney
• A/Prof Max Conway - Ophthalmologist, Save Sight Institute, Sydney Eye Hospital and The University of Sydney

RESOURCES

• Early Ocular Melanoma Patient Information Brochure
• Advanced Ocular Melanoma Patient Information Brochure
• Melanoma Education Portal

Please note that this podcast was accurate at the time of recording (November 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS, Novartis and HEINE.